Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 16/20 | 0.46 |
| ▸ | BRD2 | P25440 | 4/20 | 0.41 |
| ▸ | BRD3 | Q15059 | 4/20 | 0.41 |
| ▸ | CCL2 | P13500 | 2/20 | 0.39 |
| ▸ | EP300 | Q09472 | 1/20 | 0.39 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL482744 | 0.78 | BRD4 (0.42) | NOTUMBRD4BRD2BRD3CCL2 | |
| SCHEMBL21172514 | 0.77 | NOTUM (0.37) | NOTUMBRD4 | |
| SCHEMBL17436618 | 0.77 | NOTUM (0.37) | NOTUMBRD4 | |
| SCHEMBL2670670 | 0.76 | BRD4 (0.55) | BRD4BRD2BRD3CCL2EP300 | |
| SCHEMBL482695 | 0.76 | BRD4 (0.55) | BRD4BRD2BRD3CCL2EP300 | |
| SCHEMBL483023 | 0.76 | BRD4 (0.55) | BRD4BRD2BRD3CCL2EP300 | |
| SCHEMBL10270644 | 0.76 | NOTUM (0.55) | NOTUMBRD4BRD2BRD3CREBBP | |
| SCHEMBL18407443 | 0.68 | NOTUM (0.57) | NOTUMBRD4BRD2BRD3CREBBP | |
| SCHEMBL16062363 | 0.68 | BRD4 (0.36) | NOTUMBRD4LMNAPTGDR2 | |
| SCHEMBL11978841 | 0.68 | BRD4 (0.67) | BRD4BRD2BRD3EP300BRDT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8604030-B2 | Fused piperidine compound and pharmaceutical containing same | KOWA COMPANY, LTD. (JP) | 2013-12-10 | — | — | US | disclosed |
| US-20120108581-A1 | FUSED PIPERIDINE COMPOUND AND PHARMACEUTICAL CONTAINING SAME | KOWA COMPANY, LTD (JP) | 2012-05-03 | — | — | US | disclosed |
| EP-2412710-A1 | FUSED PIPERIDINE COMPOUND AND PHARMACEUTICAL AGENT COMPRISING SAME | Kowa Company, Ltd. (JP) | 2012-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108581-A1 | FUSED PIPERIDINE COMPOUND AND PHARMACEUTICAL CONTAINING SAME | EPOR, JAK2, HBZ | NOTUM 3926/4885BRD4 1271/4885BRD2 1467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.